Find Silatecan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ar-67, 220913-32-6, Db-67, Ar67, Db 67; silatecan, Db 67
Molecular Formula
C26H30N2O5Si
Molecular Weight
478.6  g/mol
InChI Key
XUSKJHCMMWAAHV-SANMLTNESA-N
FDA UNII
3YEA04NV6H

Silatecan
Silatecan AR-67 is a synthetic, highly lipophilic derivative of camptothecin, with potential antineoplastic and radiosensitizing activities. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces lethal double-stranded DNA breaks when encountered by the DNA replication machinery, thereby inhibiting DNA replication and inducing apoptosis. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active lactone structure to an inactive carboxylate form. Modifications on the E ring of camptothecin prevent binding of human serum albumin, which prefers the inactive carboxylate form, thereby enhancing the stability of the active lactone structure and resulting in prolonged agent activity. In addition, this agent sensitizes tumor cells toward radiation treatment.
1 2D Structure

Silatecan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(19S)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
2.1.2 InChI
InChI=1S/C26H30N2O5Si/c1-7-26(32)18-11-20-21-16(12-28(20)23(30)17(18)13-33-24(26)31)22(34(5,6)25(2,3)4)15-10-14(29)8-9-19(15)27-21/h8-11,29,32H,7,12-13H2,1-6H3/t26-/m0/s1
2.1.3 InChI Key
XUSKJHCMMWAAHV-SANMLTNESA-N
2.1.4 Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=C(C=CC(=C5)O)N=C4C3=C2)[Si](C)(C)C(C)(C)C)O
2.1.5 Isomeric SMILES
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=C(C=CC(=C5)O)N=C4C3=C2)[Si](C)(C)C(C)(C)C)O
2.2 Other Identifiers
2.2.1 UNII
3YEA04NV6H
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)- Dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9- Dihydroxy-, (4s)-

2. 7-t-butyldimethylsilyl-10-hydroxycamptothecin

3. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin

4. Ar 67 Cpd

5. Ar-67 Cpd

6. Db 67

7. Db-67

2.3.2 Depositor-Supplied Synonyms

1. Ar-67

2. 220913-32-6

3. Db-67

4. Ar67

5. Db 67; Silatecan

6. Db 67

7. Nsc-708298

8. 3yea04nv6h

9. Db67

10. (s)-11-(tert-butyldimethylsilyl)-4-ethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione

11. (20s)-7-t-butyldimethylsilyl-10-hydroxycamptothecin

12. 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9-dihydroxy-, (4s)-

13. Nci60_038363

14. Ar 67 Cpd

15. Ar-67 Cpd

16. Unii-3yea04nv6h

17. Chembl412309

18. Gtpl8919

19. Schembl1266162

20. Dtxsid00176592

21. Ar 67

22. Nsc708298

23. Zinc170020689

24. Compound 14 [pmid:11052802]

25. Db12384

26. Nsc 708298

27. Q27074492

28. (20s)-7-tert-butyldimethysilyl-10-hydroxycamptothecin

29. (19s)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione

30. 1h-pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4h,12h)dione, 11-[(1,1-dimethylethyl)dimethylsilyl]-4-ethyl-4,9-dihydroxy-, (4s)-

2.4 Create Date
2006-06-05
3 Chemical and Physical Properties
Molecular Weight 478.6 g/mol
Molecular Formula C26H30N2O5Si
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Exact Mass478.19239860 g/mol
Monoisotopic Mass478.19239860 g/mol
Topological Polar Surface Area100 Ų
Heavy Atom Count34
Formal Charge0
Complexity982
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty